Back to Search
Start Over
Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG
- Source :
- Journal of the European Academy of Dermatology and Venereology : JEADV. 36(1)
- Publication Year :
- 2021
-
Abstract
- Background Psoriasis has important physical and psychosocial effects that extend beyond the skin. Understanding the impact of treatment on health-related quality of life (HRQoL) and patient-perceived symptom severity in psoriasis is key in clinical decision-making. Objectives This post-hoc analysis of the PSO-LONG trial data assessed the impact of long-term proactive or reactive management with fixed-dose combination calcipotriene 50 µg/g and betamethasone dipropionate 0.5 mg/g (Cal/BD) foam on patient-reported outcomes (PRO) in patients with psoriasis vulgaris. Methods Five hundred and twenty-one patients from the Phase 3, randomised, double-blind PSO-LONG trial were included. An initial 4-week, open-label phase of fixed-dose combination Cal/BD foam once daily (QD) was followed by a 52-week maintenance phase, at the start of which patients were randomised to a proactive management arm (Cal/BD foam twice weekly) or reactive management arm (vehicle foam twice weekly). Patient-perceived symptom severity and HRQoL were assessed using the Psoriasis Symptom Inventory (PSI), the Dermatology Life Quality Index (DLQI) and the EuroQol-5D for psoriasis (EQ-5D-5L-PSO). Results Statistically and clinically significant improvements were observed across all PRO measures. The mean difference (standard deviation) from baseline to Week 4 was -8.97 (6.18) for PSI, -6.02 (5.46) for DLQI, and 0.11 (0.15) for EQ-5D-5L-PSO scores. During maintenance, patients receiving reactive management had significantly higher DLQI (15% [p=0.007]) and PSI (15% [p=0.0128]), and a numerically lower EQ-5D-5L-PSO mean area under the curve score compared with patients receiving proactive management (1% [p=0.0842]). Conclusions Cal/BD foam significantly improved DLQI, EQ-5D-5L-PSO, and PSI scores during the open-label and maintenance phases. Patients assigned to proactive management had significantly better DLQI and PSI scores, and numerically better EQ-5D-5L-PSO versus reactive management. Additionally, baseline flare was associated with worse PROs than the start of a relapse and patients starting a relapse also had worse PROs than patients in remission.
- Subjects :
- medicine.medical_specialty
Fixed-dose combination
Betamethasone dipropionate
calcipotriol
Dermatology
Betamethasone
chemistry.chemical_compound
Quality of life
Psoriasis
Internal medicine
Post-hoc analysis
medicine
Humans
Calcipotriol
betamethasone dipropionate
business.industry
Area under the curve
topical administration
Dermatology Life Quality Index
medicine.disease
humanities
Drug Combinations
Infectious Diseases
Treatment Outcome
chemistry
Quality of Life
Dermatologic Agents
business
psoriasis
medicine.drug
Subjects
Details
- ISSN :
- 14683083
- Volume :
- 36
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Journal of the European Academy of Dermatology and Venereology : JEADV
- Accession number :
- edsair.doi.dedup.....fea2872aeb62d5fd6f7b62e435689f6a